I'm expecting that the upcoming trial results will determine the timeline for considering offers - if the PMS outcomes are replicated, then it would indicate with a deal of confidence, that NNZ-2591 would be beneficial for people with other disorders both within and without of the autism spectrum.
The timing of the AGM on 28th May would seem almost perfect - can't wait to attend.
Ann: 2023 Annual Report to shareholders, page-192
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$23.97 |
Change
3.260(15.7%) |
Mkt cap ! $3.060B | |||
| Open | High | Low | Value | Volume |
| $23.00 | $24.00 | $21.60 | $27.11M | 1.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 942 | $23.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.97 | 27 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$24.00 |
Change
3.260 ( 16.0 %) |
||||
| Open | High | Low | Volume | ||
| $22.98 | $24.00 | $21.60 | 310545 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| NEU (ASX) Chart |